Browse > Article
http://dx.doi.org/10.4046/trd.2010.68.1.22

Immunohistochemical Expression and Prognostic Value of VEGF, HIF-$1{\alpha}$, EGFR in Non-Small Cell Lung Cancer  

Kim, Myung-Sook (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
Park, Sung-Hak (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.68, no.1, 2010 , pp. 22-28 More about this Journal
Abstract
Background: Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis. VEGF production is regulated by HIF-$1{\alpha}$ and EGFR. This study examined the relationship between the clinicopathological factors and VEGF, HIF-$1{\alpha}$ and EGFR protein overexpression, and evaluated their prognostic value in patients with a surgically resected non-small cell lung cancer (NSCLC). Methods: Patients who underwent a surgical resection at Kangnam St. Mary's hospital were reviewed retrospectively. The core biopsy samples from 54 patients with NSCLC were assembled on a tissue microarray (TMA), and immunohistochemical staining for the VEGF, HIF-$1{\alpha}$ and EGFR proteins was performed. The overexpression of these proteins was evaluated in relation to age, gender, histology and staging by univariate analysis. The clinicopathological prognostic factors were analyzed. Results: Multivariate analysis performed by Cox regression (odds ratio 2.8, 95% CI 1.0~8.2, p=0.046) revealed HIF-$1{\alpha}$ overexpression to be an unfavorable factor. There was no correlation between the overexpression of these proteins and the clinicopathological factors. VEGF showed a positive relationship with EGFR, but there was no statistical significance [$p(x^2)=0.06$]. Conclusion: HIF-$1{\alpha}$ overexpression predicts shorter survival in patients with a surgically resected NSCLC. Therefore, HIF-$1{\alpha}$ may be a poor prognostic factor in NSCLC.
Keywords
Carcinoma; Non-Small-Cell Lung; Immunohistochemistry; Prognosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.   DOI   ScienceOn
2 Cho SR, Byun JH, Kim JI, Lee BG, Chun BK. Expression of hypoxia-inducible factor-1alpha in non-small cell lung cancer: relationship to prognosis and tumor biomarkers. Korean J Thorac Cardiovasc Surg 2006;39:828-37.
3 Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-6.   DOI   ScienceOn
4 Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan S, Tastepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 2007;38:764-8.   DOI   ScienceOn
5 Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006;61:140-5.   DOI   ScienceOn
6 Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.   DOI   ScienceOn
7 Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40.   DOI   ScienceOn
8 Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70:1469-80.   DOI   ScienceOn
9 Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.   DOI
10 Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
11 Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally upregulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.
12 Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006;66:3197-204.   DOI   ScienceOn
13 Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol 2007;8:460-1.   DOI   ScienceOn
14 Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable nonsmall cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85:881-90.   DOI   ScienceOn
15 Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
16 Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.   DOI   ScienceOn
17 Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20:975-81.   DOI   ScienceOn
18 Han H, Silverman JF, Santucci TS, Macherey RS, d' Amato TA, Tung MY, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-9.   DOI   ScienceOn
19 Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
20 Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.   DOI
21 Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986;55:244-8.
22 Schmidt LH, Biesterfeld S, Kummel A, Faldum A, Sebastian M, Taube C, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009;29:201-9.
23 Ahn JH, Kim SW, Hong SM, Suh C, Kim WK, Lee IC, et al. Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci 2004;19:529-35.   과학기술학회마을   DOI   ScienceOn
24 Bremnes RM, Camps C, Sirera R. Angiogenesis in nonsmall cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58.   DOI   ScienceOn